Variable Solitary Fibrous Tumor Locations: CT and MR Imaging Features.

Variable Solitary Fibrous Tumor Locations: CT and MR Imaging Features.
复制标题

可变的孤立性纤维性肿瘤位置 CT 和 MR 成像特征

DOI:
10.1097/md.0000000000003031
复制
发表时间:
2016-03
期刊:
影响因子:
1.6
通讯作者:
Yicheng N
Yicheng N
中科院分区:
医学4区
文献类型:
--
作者:
Zhanlong M;Haibin S;Xiangshan F;Jiacheng S;Yicheng N

文献摘要

被引文献

相似文献

本研究的目的是描述不同部位的孤立性纤维肿瘤(SFT)的影像学特征,并提出组织病理学相关性。2007年至2013年,对20例经组织学证实的SFT病例进行了回顾性分析,包括计算机断层扫描(CT; 9/20)、磁共振成像(MRI; 5/20)或CT和MRI(6/20)。所有20例SFT均为边界清楚的小叶软组织肿块,60%位于胸膜外。1例胸膜侵犯至第10胸椎并有肺转移。图像显示11个异质性病灶,沿着最大轴超过3.0± 0.203 cm,伴斑片状坏死灶,9个同质性病灶<3.0 ± 0.203 cm。     显微镜下,所有SFT均为增殖性梭形细胞,伴有不同程度的纤维化和散在的血管分支。细胞对CD 34呈强免疫阳性。在这里,我们回顾了各种影像学表现的SFT,它可以在胸膜以及其他浆膜组织,如脑膜和腹膜后。沿最大轴沿着大于3.0 ± 0.203 cm的SFT呈混合型,而小于3.0 ± 0.203 cm的SFT呈等密度型。      SFTs细胞为CD 34免疫阳性,手术是一线治疗选择。
The aim of the study is to describe the radiological imaging features of different solitary fibrous tumors (SFTs) locations and present histopathological correlations. From 2007 to 2013, 20 cases of histologically confirmed that SFTs were retrospectively analyzed with computed tomography (CT; 9/20), magnetic resonance imaging (MRI; 5/20), or both CT and MRI (6/20). All 20 SFTs were well defined, lobular, soft-tissue masses, and 60% were located outside of the pleura. One pleural case invaded to the 10th thoracic vertebra and had lung metastases. Images revealed 11 heterogeneous lesions that exceeded 3.0 ± 0.203 cm along the greatest axis with patchy necrotic foci, and 9 homogeneous lesions <3.0 ± 0.203. Microscopically, all SFTs were proliferative spindle cells with varying degrees of fibrosis and interspersed vessel branching. Cells were strongly immunopositive for CD34. Here we review variable imaging findings of SFTs, which can be within the pleura as well as within other serosal tissues such as the meninges and postperitoneum. SFTs > 3.0 ± 0.203 cm along the greatest axis appeared to be mixed patterns, whereas SFTs < 3.0 ± 0.203 cm had isodense appearances. SFTs cells were CD34 immunopositive and surgery was a first-line treatment choice.